SERVIER
PharmaSERVIER is a pharmaceutical company focused on Oncology, Cardiovascular, Gastroenterology. Key products include TIBSOVO.
FDA Novel Drug Designations
(2018-2024)SERVIER's Key Drugs
SERVIER's core commercial portfolio centers on TIBSOVO, VORANIGO, spanning Oncology and Cardiovascular — its most strategically important drugs approved in the last 15 years.
SERVIER's Recent FDA Approvals
SERVIER secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.
SERVIER's Therapeutic Areas
SERVIER's approved drugs and pipeline span 4 therapeutic areas, led by Oncology and Cardiovascular, across 0 biologic and 2 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
SERVIER's Top Competitors
SERVIER's closest competitors by therapeutic-area and drug-target overlap include Takeda, Merck, and Baxter. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
SERVIER Pipeline Snapshot
SERVIER has 14 active clinical programs from ClinicalTrials.gov — 4 Phase 3, 1 Phase 2 and 9 Phase 1.
Phase 3 Readout Calendar Pro
1 Phase 3 trial with confidence-graded primary completion dates.
Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • TIBSOVO leads revenue
- • 2 key drugs tracked
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 4/14 completed
- • Speed: 36 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges